Homoharringtonine promotes BCR-ABL degradation through the p62-mediated autophagy pathway

Drug resistance to tyrosine kinase inhibitors (TKIs) is currently a clinical problem in patients with chronic myelogenous leukemia (CML). Homoharringtonine (HHT) is an approved treatment for adult patients with chronic- or accelerated-phase CML who are resistant to TKIs and other therapies; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Su, Bo, Zhilei, Jiang, Ying, Song, Xianmin, Wang, Chun, Tong, Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908937/
https://www.ncbi.nlm.nih.gov/pubmed/31789418
http://dx.doi.org/10.3892/or.2019.7412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908937/
https://www.ncbi.nlm.nih.gov/pubmed/31789418
http://dx.doi.org/10.3892/or.2019.7412

Ejemplares similares